IMB-101 is a bispecific antibody targeting OX40L and TNF, allowing simultaneous control of both adaptive and innate immune responses. As a result, our immuno-modulatory antibody drug candidate can overcome the low response rate of existing treatments, which is a major unmet medical need for rheumatoid arthritis patients. The addition of OX40-OX40L signal blockage stabilizes the over-activated immune system as well as inflammatory cytokines, leading to the reduction of autoantibodies. Thus, IMB-101 can be an effective novel treatment option for the patients unresponsive or refractory to anti-TNF agents.

OX40L is a key regulator of the immune system, capable of bidirectionally activating T cells and antigen presenting cells and inducing differentiation. It also contributes to the production of autoantibody, an important pathogen in autoimmune diseases.

IMB-102 is a human monoclonal antibody targeting OX40L. By controlling the OX40-OX40L signal, it induces immune homeostasis in patients by downregulating over-activated effector T cells and expanding the regulatory T cell population. Our immuno-modulatory antibody can be applied to treat various autoimmune and inflammatory diseases caused by immune dysregulation.

TNF is a major inflammatory cytokine observed in rheumatoid arthritis patients, and various inhibitors have been developed to control TNF. However, the efficacy of TNF inhibitors has been less than satisfactory, and in particular, ACR70 response is observed in less than 50% of the treated patients. Thus, there remains an unmet need for the development of an effective treatment option for TNF refractory patients. IMB-101 is an innovative immuno-modulatory antibody drug that can induce short-term inflammation reduction by controlling TNF and achieve long-term homeostasis of the immune system by blocking the OX40L signal. It has exhibited TNF blocking efficacy comparable to Humira at the same molar concentration while effectively blocking OX40L simultaneously.